- Home
- NXC vs NSPR Comparison
NXC vs NSPR Comparison
Compare NXC & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXC | NSPR |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 81.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXC | NSPR |
|---|---|---|
| Price | $13.19 | $1.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 17.5K | ★ 59.6K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | N/A | $75.45 |
| P/E Ratio | $70.47 | ★ N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $11.86 | $1.59 |
| 52 Week High | $13.70 | $3.80 |
Technical Indicators
Market Signals| Indicator | NXC | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 39.81 |
| Support Level | $13.13 | $1.89 |
| Resistance Level | $13.29 | $2.15 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 79.07 | 25.49 |
Price Performance
Historical ComparisonAbout NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.